High-dose pemetrexed in combination with high-dose crizotinib for the treatment of refractory CNS metastases in ALK-rearranged non-small-cell lung cancer

J Thorac Oncol. 2013 Jan;8(1):e3-5. doi: 10.1097/JTO.0b013e3182762d20.

Authors

Leena Gandhi¹, Jan Drappatz, Nikhil H Ramaiya, Gregory A Otterson

Affiliation

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. [email protected]

PMID: 23242445
DOI: 10.1097/JTO.0b013e3182762d20

No abstract available

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Anaplastic Lymphoma Kinase
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Brain Neoplasms / secondary
Brain Neoplasms / therapy*
Carcinoma, Non-Small-Cell Lung / genetics
Carcinoma, Non-Small-Cell Lung / secondary
Carcinoma, Non-Small-Cell Lung / therapy*
Chemoradiotherapy
Crizotinib
Glutamates / administration & dosage
Guanine / administration & dosage
Guanine / analogs & derivatives
Humans
Lung Neoplasms / genetics
Lung Neoplasms / pathology
Lung Neoplasms / therapy*
Male
Pemetrexed
Pyrazoles / administration & dosage
Pyridines / administration & dosage
Radiosurgery
Receptor Protein-Tyrosine Kinases / genetics*

Substances

Glutamates
Pyrazoles
Pyridines
Pemetrexed
Crizotinib
Guanine
ALK protein, human
Anaplastic Lymphoma Kinase
Receptor Protein-Tyrosine Kinases